This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

27 Aug 2012

Just three new breast cancer drugs to drive market growth

A new Decision Resources report has made predictions about the breast cancer drug market through 2021.

The breast cancer drug market is likely to be bolstered by just three new entrants through to 2021, experts have forecast.


Research and advisory firm Decision Resources predicts that market growth will be driven by Roche and Genentech's pertuzumab (brand name Perjeta) and trastuzumab-DM1 (T-DM1), and by Novartis' everolimus (Afinitor).


Everolimus is expected to achieve major-market peak-year sales in excess of $1 billion, having already secured US and European approval for the treatment of hormone-receptor-positive breast cancer.


Pertuzumab is anticipated to secure blockbuster sales by 2021, while T-DM1 is yet to be approved but has demonstrated impressive results in the treatment of HER2-positive disease.


Amy Duval, an analyst at Decision Resources, said: "Breast cancer drug development is a hive of activity but despite the busy pipeline, we forecast the uptake of just three novel agents in

Related News